XOMA Corp represents values of innovation, collaboration, and integrity in the biotechnology industry. With a strong corporate philosophy focused on advancing the discovery and development of transformative medicines, XOMA Corp strives to improve patients' lives through its cutting-edge research and development efforts. By fostering strategic partnerships and utilizing its expertise in antibody discovery and optimization, XOMA Corp aims to address significant medical challenges and deliver meaningful solutions. The company's commitment to scientific excellence, ethical practices, and patient-centric approach truly defines their values and corporate philosophy. Through their dedication, XOMA Corp continues to make a positive impact in the field of biotechnology.

XOMA Corp is primarily present in the United States.

XOMA Corp has achieved several significant milestones. The company successfully developed and commercialized XOMA 357, a potent antibody, for the treatment of patients with rare genetic disorders. XOMA Corp also reached important partnerships and collaborations with leading pharmaceutical companies, expanding its pipeline and reaching broader markets. Moreover, XOMA Corp has been granted multiple patents for their innovative technologies and therapeutic approaches. These achievements solidify XOMA Corp's commitment to medical advancements and its position as a key player in the biopharmaceutical industry.

XOMA Corp, a renowned biotech company, has a rich history and an impressive background. Established in 1981, XOMA has been at the forefront of developing innovative antibody-based therapeutics. Initially focusing on hybridoma technology, the company rapidly advanced into antibody discovery and optimization. Over the years, XOMA has established strategic collaborations with leading pharmaceutical companies, enabling them to expand their research and development efforts. With a strong emphasis on novel drug discovery, XOMA has successfully developed multiple therapeutic candidates, particularly in the areas of immunology and inflammation. With its distinguished track record, XOMA Corp stands as a pioneering force in the biotech industry, consistently striving for breakthrough medical advancements.

The main competitors of XOMA Corp in the market are companies such as BioMarin Pharmaceutical Inc., Amgen Inc., and Regeneron Pharmaceuticals Inc.

XOMA Corp is primarily active in the biotechnology industry.

XOMA Corp operates under a biotech business model. The company focuses on developing innovative therapeutics to address unmet medical needs. XOMA Corp utilizes its proprietary antibody discovery and optimization technologies to create potential breakthrough drugs for various diseases, including immunology, oncology, and metabolic disorders. By leveraging strategic partnerships and collaborations, XOMA Corp seeks to advance its pipeline of therapeutic candidates and bring them to market. With its strong emphasis on research and development, XOMA Corp aims to revolutionize healthcare by providing effective treatment options for patients worldwide.

Az XOMA Royalty P/E mutatója -218,51.

Az XOMA Royalty KUV 11,81.

Az AlleAktien Minőségi Score XOMA Royalty esetében 2/10.

A várt XOMA Royalty forgalma 26,49 Mió. USD.

A(z) várt XOMA Royalty nyereség -1,43 Mió. USD.

The XOMA Corporation is a biotechnology company that focuses on the discovery and development of new drugs. Its business activities can be divided into four main divisions: research and development, licensing, production, and clinical testing. Research and development is one of the key pillars of XOMA. The company utilizes an innovative technology platform to develop new drugs. It employs the so-called antibody technology, which enables the development of drugs targeting specific cancer cells, autoimmune reactions, and infectious diseases. Licensing of technologies is also an important component of XOMA's business model. The company's technology platform allows for the development of novel antibodies for diagnosing and treating diseases. Other companies can utilize this technology by paying licensing fees. Production is another crucial factor at XOMA. The company owns a bioreactor production facility capable of producing antibodies on a large scale. This allows the company to manufacture its own drugs in large quantities. It is also possible to license the production level to other companies. Last but not least, clinical testing plays a central role at XOMA. After the development of new drugs, they must undergo clinical testing to confirm their efficacy and safety. XOMA also utilizes these testing phases to set medical standards and expand its own portfolio. XOMA currently possesses several products available on the market and used in the treatment of various diseases. The most well-known product is Hieronymus, a drug for treating numerous autoimmune diseases, including rheumatoid arthritis. Other products include Gevokizumab, a drug for treating non-infectious inflammatory diseases, XOMA 358, a drug for treating hyperinsulinism, and Erenumab, a drug for migraines. In summary, XOMA Corporation's business model is suitable for establishing the company as a key player in the biotechnology and pharmaceutical industries. Through constant innovation, technology licensing, and clinical testing, it is possible to bring new drugs to the market and expand the company's product portfolio.

A(z) XOMA Royalty évente alkalommal oszt ki 0 USD összegű osztalékot.

A XOMA Royalty esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) XOMA Royalty ISIN kódja: US98419J2069.

A XOMA Royalty WKN-je A2ATUH.

Az XOMA Royalty tőzsdei rövidítése XOMA.

Az elmúlt 12 hónapban a(z) XOMA Royalty osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) XOMA Royalty várhatóan 0 USD összegű osztalékot fog fizetni.

A(z) XOMA Royalty jelenlegi osztalékhozama .

A(z) XOMA Royalty negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A XOMA Royalty az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 USD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) XOMA Royalty a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, XOMA Royalty által 2024. 09. 08.-án/én fizetett 0 USD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 09. 08.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 09. 08. időpontban történt.

2023 évben a XOMA Royalty 0 USD összegű osztalékot fizetett ki.

Az XOMA Royalty osztalékait USD fizeti ki.